McCarthy Sean A.'s Insider Trades & SAST Disclosures
McCarthy Sean A.'s most recent trade in CytomX Therapeutics Inc was a trade of 800,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 4, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern McCarthy Sean A..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 800,000 | 800,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 390,000 | 390,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 195,000 | 1,032,851 (2%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 180,000 | 837,851 (1%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2024 | 37,500 | 671,749 (1%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2024 | 37,500 | 0 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Sale of securities on an exchange or to another person at price $ 1.23 per share. | 20 Aug 2024 | 13,898 | 657,851 (1%) | 0% | 1.2 | 17,082 | Common Stock |
| CytomX Therapeutics Inc | McCarthy Sean A. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 109,768 | 0 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean McCarthy A. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 26 Mar 2024 | 109,768 | 634,249 (1%) | 0% | 1.6 | 172,874 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Sale of securities on an exchange or to another person at price $ 2.09 per share. | 19 Mar 2024 | 20,223 | 524,481 (1%) | 0% | 2.1 | 42,175 | Common Stock |
| CytomX Therapeutics Inc | Sean McCarthy A. | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 420,000 | 420,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 260,000 | 260,000 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 90,000 | 544,704 (1%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | A. Sean McCarthy | Director, CEO | Sale of securities on an exchange or to another person at price $ 1.38 per share. | 20 Dec 2023 | 13,551 | 454,704 (0%) | 0% | 1.4 | 18,710 | Common Stock |
| CytomX Therapeutics Inc | Sean McCarthy A. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2023 | 37,500 | 468,255 (1%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | A. Sean McCarthy | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2023 | 37,500 | 37,500 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | A. McCarthy Sean | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Sep 2023 | 40,000 | 445,356 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | McCarthy Sean A. | Director, CEO | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 20 Sep 2023 | 14,601 | 430,755 (0%) | 0% | 1.3 | 18,987 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 19 May 2023 | 16,535 | 405,356 (0%) | 0% | 1.6 | 26,041 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 May 2023 | 16,535 | 119,536 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Sale of securities on an exchange or to another person at price $ 1.88 per share. | 16 Mar 2023 | 7,121 | 388,821 (0%) | 0% | 1.9 | 13,391 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 315,000 | 315,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 300,000 | 300,000 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 105,000 | 395,942 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2022 | 40,000 | 305,853 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 1.42 per share. | 19 Jul 2022 | 14,911 | 290,942 (0%) | 0% | 1.4 | 21,206 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2022 | 66,742 | 0 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.94 per share. | 09 May 2022 | 66,742 | 241,664 (0%) | 0% | 0.9 | 63,071 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.95 per share. | 09 May 2022 | 24,189 | 265,853 (0%) | 0% | 0.9 | 22,859 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2022 | 24,189 | 0 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 75,000 | 174,922 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 80,000 | 80,000 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 11 Aug 2021 | 92,113 | 99,922 (0%) | 0% | 1.1 | 104,447 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2021 | 92,113 | 0 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 16 Jun 2021 | 100,000 | 93,118 (0%) | 0% | 7.0 | 704,470 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2021 | 30 | 92,113 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 14 Jun 2021 | 30 | 7,839 (0%) | 0% | 1.1 | 34 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 14 Jun 2021 | 10 | 7,849 (0%) | 0% | 0.9 | 9 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2021 | 10 | 66,742 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2021 | 100,000 | 92,143 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.49 per share. | 31 Mar 2021 | 100,000 | 206,894 (0%) | 0% | 7.5 | 749,470 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 31 Mar 2021 | 100,000 | 306,894 (0%) | 0% | 1.1 | 113,390 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2020 | 100,000 | 192,143 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 23 Dec 2020 | 100,000 | 206,894 (0%) | 0% | 1.1 | 113,390 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 6.39 per share. | 30 Nov 2020 | 930 | 106,894 (0%) | 0% | 6.4 | 5,945 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2020 | 20,500 | 0 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.61 per share. | 21 Sep 2020 | 20,500 | 105,964 (0%) | 0% | 6.6 | 135,601 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 5.11 per share. | 29 May 2020 | 1,158 | 85,464 (0%) | 0% | 5.1 | 5,916 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2020 | 36,000 | 292,143 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 12 May 2020 | 36,000 | 84,306 (0%) | 0% | 15 | 540,000 | Common Stock |
| CytomX Therapeutics Inc | Sean A. McCarthy | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.13 per share. | 12 May 2020 | 36,000 | 120,306 (0%) | 0% | 1.1 | 40,820 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges